Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esketamine - Auris Medical/INSERM/University of Montpellier

Drug Profile

Esketamine - Auris Medical/INSERM/University of Montpellier

Alternative Names: (s)-ketamine; AM-101; Esketamine otic gel; Keyzilen

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Auris Medical; INSERM; University of Montpellier I
  • Developer Auris Medical
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Tinnitus

Most Recent Events

  • 13 Sep 2019 Auris Medical receives advice from the US FDA and the EMA for esketamine in Tinnitus
  • 31 Jul 2019 Phase III development is ongoing United Kingdom, Austria, Hungary, Germany, Belgium, Poland, Spain, Canada, USA, Czech Republic and South Korea (Intratympanic)
  • 25 Apr 2019 Auris Medical plans regulatory filing for marketing authorisation of esketamine in Tinnitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top